Buying pressure lifts Injective price higher in today's trading

Traders Union
All News
Crypto
Injective surges 10.37% today to $3.27

Highlights

Injective enhances its institutional footprint in Japan by adding Next Finance Tech, a leading regulated web3 infrastructure provider, as a validator.
Next Finance Tech's established compliance and operational reliability is expected to promote greater institutional and regulated blockchain adoption in Japan.
INJ/USD trades with short-term bullish momentum but faces overbought indicators, with an expected consolidation range of $3.00 to $3.67 and a downside risk bias.

Institutional adoption advances as Next Finance Tech joins as validator

Injective expands its presence in Japan by adding Next Finance Tech, a major local web3 infrastructure provider, as an active validator. Founded by former Goldman Sachs employees, Next Finance Tech is recognized for compliant and reliable node operations. This development is expected to support Injective's institutional adoption and regulated activity in the Japanese blockchain sector.

Anton Kharitonov, expert at Traders Union, emphasizes the persistent long-term bearish structure for INJ despite its recent uptick. He finds today’s upside momentum at odds with mixed momentum readings and pronounced overbought signals on several oscillators. Kharitonov remains especially wary as none of the four weekly indicators show bullish conviction. While the Next Finance Tech validator news may aid sentiment, the price remains far below the 200-day average. "Such short-term rallies are unreliable when the broader trend and weekly signals remain bearish — traders should expect a likely reversal if $3.00 is breached."

Viktoras Karapetjanc, expert at Traders Union, sees positive structural developments in Injective’s partnership with Next Finance Tech. He believes this step signals growing institutional adoption and regulatory support within Japan’s blockchain ecosystem. Karapetjanc regards today’s price jump and expanding validator network as clear opportunities for further growth. He confidently states, "With a bullish structure building and institutional traction rising, I expect Injective to attract new buyers and challenge the $3.67 resistance soon."

Parshwa Turakhiya, analyst, notes the robust intraday buying in INJ but highlights overbought signals flagged by Stochastic RSI and CCI. He sees room for a short-term pullback or sideways move as traders digest recent gains and consider conflicting momentum cues. The $3.00 support and $3.67 resistance form the key tactical range for now. He concludes, "Given mixed momentum and overbought oscillators, I see the best short-term opportunities within the volatility band rather than chasing breakouts."

Bullish momentum challenged by long-term resistance and overbought signals

INJ/USD is currently trading well above the 20-day and 50-day moving averages ($2.90 and $2.99), suggesting positive short- and medium-term momentum, but remains far below the 200-day average ($5.41), which keeps the long-term structure bearish. The nearest dynamic support is at the Ichimoku Kijun level ($2.99), with resistance expected near the $3.50 round level if the current move extends. Looking at momentum, the Moving Average Convergence Divergence (MACD) and Average Directional Index (ADX) on the daily chart both show neutral readings, indicating a lack of strong trend conviction. Several oscillators send mixed messages: the Relative Strength Index (RSI) is moderate at 50.59 and signals buying interest, while the Stochastic RSI flags strong overbought conditions and the Commodity Channel Index (CCI) is also at an overbought level. Bull/Bear Power (BBP) shows a clear dominance by buyers, supporting today’s buying pressure. The Awesome Oscillator agrees, reinforcing the bullish tone. The session began with an upside gap of about $0.02 and surged 10.37% to $3.27, placing the price near the session’s high in a volatile 9.06% daily range, signaling enduring strength toward the highs. Oscillator overbought signals and mixed momentum readings reveal divergence, so the intraday momentum currently outweighs signaling caution for short-term overextension.

Earlier, analysts noted that Injective was locked in a bearish technical structure with limited prospects for a decisive upward move. The recent upside surge and institutional developments in Japan introduce potential for a shift in momentum, but with oscillators signaling overextension and the long-term trend still negative, traders should watch for a possible return to consolidation if resistance near $3.67 holds.

Source of Data: INJ Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.